Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
[lymphangioleiomyomatosis]
Mutations
of
the
tumor
suppressor
genes
tuberous
sclerosis
complex
(
TSC
)
1
and
TSC
2
cause
pulmonary
lymphangioleiomyomatosis
(
LAM
)
and
tuberous
sclerosis
(
TS
)
.
Current
rapamycin-based
therapies
for
TS
and
LAM
have
a
predominantly
cytostatic
effect
,
and
disease
progression
resumes
with
therapy
cessation
.
Evidence
of
RhoA
GTPase
activation
in
LAM
-derived
and
human
TSC
2
-
null
cells
suggests
that
3
-
hydroxy-
3
-
methylglutaryl-coenzyme
A
reductase
inhibitor
statins
can
be
used
as
potential
adjuvant
agents
.
The
goal
of
this
study
was
to
determine
which
statin
(
simvastatin
or
atorvastatin
)
is
more
effective
in
suppressing
TSC
2
-
null
cell
growth
and
signaling
.
Simvastatin
,
but
not
atorvastatin
,
showed
a
concentration-dependent
(
0
.
5
-
10
μM
)
inhibitory
effect
on
mouse
TSC
2
-
null
and
human
LAM
-derived
cell
growth
.
Treatment
with
10
μM
simvastatin
induced
dramatic
disruption
of
TSC
2
-
null
cell
monolayer
and
cell
rounding
;
in
contrast
,
few
changes
were
observed
in
cells
treated
with
the
same
concentration
of
atorvastatin
.
Combined
treatment
of
rapamycin
with
simvastatin
but
not
with
atorvastatin
showed
a
synergistic
growth
-inhibitory
effect
on
TSC
2
-
null
cells
.
Simvastatin
,
but
not
atorvastatin
,
inhibited
the
activity
of
prosurvival
serine-threonine
kinase
Akt
and
induced
marked
up-regulation
of
cleaved
caspase-
3
,
a
marker
of
cell
apoptosis
.
Simvastatin
,
but
not
atorvastatin
,
also
induced
concentration-dependent
inhibition
of
p
42
/
p
44
Erk
and
mTORC
1
.
Thus
,
our
data
show
growth
-inhibitory
and
proapoptotic
effects
of
simvastatin
on
TSC
2
-
null
cells
compared
with
atorvastatin
.
These
findings
have
translational
significance
for
combinatorial
therapeutic
strategies
of
simvastatin
to
inhibit
TSC
2
-
null
cell
survival
in
TS
and
LAM
.
Diseases
Validation
Diseases presenting
"synergistic growth-inhibitory effect"
symptom
lymphangioleiomyomatosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom